Frequently Asked Questions

Psychedelics are not categorically safe or unsafe — they exist on a risk spectrum that depends heavily on the substance, dose, your personal health history, your mental state, your environment, and whether you have support.

What we know reduces risk:

• Testing your substances with reagent kits and fentanyl strips
• Knowing your dose and starting low
• Understanding drug interactions (especially with SSRIs, MAOIs, and lithium)
• Having a sober sitter present for macrodoses
• Preparing your set (mindset) and setting (environment)
• Knowing when NOT to trip (see our guide)

What increases risk:

• Taking unknown substances from unreliable sources
• High doses without experience
• Combining with alcohol, stimulants, or contraindicated medications
• Using alone at high doses
• Using during acute mental health crisis
• Ignoring family history of psychotic disorders

In clinical trials with screened participants, prepared environments, and professional support, serious adverse events are rare. In uncontrolled recreational settings, risks are higher — mostly due to behavioral accidents, dangerous adulterants, and contraindicated health conditions.

The honest answer: psychedelics can be used relatively safely, but they are not risk-free, and they can be dangerous for some people in some circumstances.

The short answer: sometimes, for some people, and not by themselves.

Clinical trials have produced genuinely exciting results. In Johns Hopkins studies, two doses of psilocybin plus therapy led to rapid depression symptom reduction for many participants — with about half meeting remission criteria at four weeks. Similar signals exist for PTSD with MDMA-assisted therapy, though the FDA declined approval in 2024 pending additional data.

But here’s what the headlines often miss:

It’s not just the drug. All the strongest studies involve extensive preparation, supervised sessions, and structured integration therapy. You can’t buy the results of a Johns Hopkins trial at a festival.

The placebo effect is enormous. Expectations shape psychedelic experiences profoundly. Some benefits may come from the full therapeutic container rather than pharmacology alone.

Results are mixed. Not everyone benefits. Some people feel worse. We don’t yet know how to predict who will respond.

Durability is unclear. Most studies follow people for weeks or months. Long-term data over years is still limited.

Microdosing is especially uncertain. Multiple placebo-controlled studies now suggest microdosing benefits are largely indistinguishable from placebo.

If you’re struggling with depression or anxiety, psychedelics are not a first-line treatment. Evidence-based options like therapy (CBT, ACT, DBT), psychiatric medication, exercise, and sleep improvement have stronger, more established track records. Psychedelics may become part of the toolkit in the future, but they are not a guaranteed fix now.

A macrodose (full dose) is enough to produce significant alterations in consciousness — changes in perception, thought, emotion, and sense of self. This is what people mean by “a trip.” A macrodose typically lasts 6–12 hours and requires a full day set aside plus time afterward for recovery and integration.

A microdose is about 1/10th to 1/20th of a full dose — small enough to be subtle or imperceptible. The idea is to go about your normal day with a slight shift in mood, creativity, or emotional flexibility. You should not feel “high” on a proper microdose.

Evidence comparison:

• Macrodose therapy has strong clinical trial evidence for depression, end-of-life anxiety, and (pending further review) PTSD.
• Microdosing has much weaker evidence. Rigorous placebo-controlled studies increasingly suggest that reported benefits are largely placebo effects.

Risk comparison:

• Macrodoses carry higher acute psychological risk (difficult experiences, anxiety) but are typically taken less frequently.
• Microdoses have lower per-dose risk but involve chronic exposure with unknown long-term safety data.

See our full guide on Microdosing vs. Macrodosing for protocols, realistic expectations, and risk details.

This is one of the most common fears, and it’s completely valid.

On a moderate to high dose of a classical psychedelic, you will experience altered perception, intense emotions, and a loosening of your usual sense of self. Your decision-making and perception of reality will be impaired. In that sense, yes — you surrender ordinary control.

But here’s the nuance:

You won’t lose motor control the way you might with alcohol or sedatives. You can generally walk, speak (though you may prefer not to), and interact with your environment. You won’t “black out” in the conventional sense.

You retain some capacity to influence the experience. Changing your posture, moving rooms, changing music, or focusing on your breath can all shift the quality of the experience.

A sitter protects you. A sober, trusted person ensures you don’t act on impaired judgment in unsafe ways.

The experience is temporary. No matter how intense, it will end. Psilocybin effects typically resolve within 6–8 hours; LSD within 8–12 hours.

The paradox of psychedelics is that the more you fight to maintain control, the more anxious and difficult the experience tends to become. Learning to surrender — while maintaining physical safety through preparation and support — is part of the work.

If the idea of surrendering control is terrifying to you, that doesn’t mean you can’t benefit from psychedelics. But it suggests starting with a lower dose, in a highly controlled setting, with an experienced sitter you deeply trust.

Classical psychedelics like psilocybin and LSD do not produce classical addiction in the way opioids, alcohol, nicotine, or even cocaine do. They don’t create the compulsive use patterns, withdrawal symptoms, or dopamine-driven craving cycles characteristic of addictive substances.

Why? Psychedelics rapidly build tolerance. Taking psilocybin two days in a row produces dramatically diminished effects. This biochemical ceiling makes daily compulsive use practically impossible.

However:

• Psychological dependence is possible. Some people become reliant on psychedelic experiences to escape ordinary life, avoid doing difficult work, or repeatedly chase peak experiences.
• Behavioral patterns can form. Using more frequently than you intended, neglecting responsibilities, or feeling unable to integrate without another dose are warning signs.
• MDMA carries higher risk. While not classically addictive, MDMA has more abuse potential than classical psychedelics and carries significant neurotoxicity risks with frequent use. Monthly use is considered an absolute minimum interval by harm reduction communities; less frequent is strongly preferred.

The integration-focused approach — using these substances deliberately, with preparation and reflection, not as an escape — is the best protection against problematic use patterns.

This is one of the most important questions, and the answer depends on which medication you’re taking.

SSRIs and SNRIs (e.g., Zoloft, Lexapro, Effexor, Cymbalta)

Interaction risk: Moderate. Serotonin syndrome is possible but relatively rare with classical psychedelics. More commonly, SSRIs/SNRIs significantly blunt psychedelic effects, leading people to take higher doses.

Do not stop your medication suddenly to take psychedelics. SSRI/SNRI withdrawal can be severe and dangerous, including brain zaps, mood swings, and suicidality. Any taper must be medically supervised and gradual.

The safest path: Talk to your prescribing physician. Some people find that the blunted effects are still meaningful. Others, with medical guidance, may taper off medications that are no longer needed. This is an individual medical decision.

MAOIs (e.g., Nardil, Parnate)

Dangerous. MAOIs combined with psychedelics — especially DMT/ayahuasca — can cause fatal serotonin syndrome or hypertensive crisis. If you take an MAOI, psychedelics are contraindicated without explicit specialist guidance.

Lithium

Dangerous. Lithium plus LSD or psilocybin carries a documented seizure risk. If you take lithium, psychedelics are contraindicated.

Trazodone and Trazodone-like medications

These can significantly dampen or block psychedelic effects.

Other psychiatric medications

Buspirone, mood stabilizers, antipsychotics, and benzodiazepines all have variable interactions. Consult your prescriber and review our Combination Safety Table.

See our full guide on Talking to Your Doctor for how to have this conversation.

Yes. Difficult psychedelic experiences — what people call “bad trips” — are a real and common possibility. Estimates vary, but somewhere between 10% and 40% of psychedelic users report at least one significantly difficult experience, depending on dose, substance, and setting.

But “bad trip” is a blunt term. Difficult experiences exist on a spectrum:

• Mild anxiety or confusion that passes in minutes
• Intense fear or paranoia lasting an hour or two
• Encountering traumatic memories that feel overwhelming
• Ego dissolution interpreted as dying — terrifying in the moment, often meaningful in retrospect
• Prolonged psychological disturbance persisting days or weeks (rare but real)

Why Difficult Experiences Happen

• Taking a higher dose than prepared for
• Resisting or fighting the experience
• Suppressed trauma or grief surfacing
• Poor set or setting (anxious mindset, unsafe environment)
• Physical discomfort or feeling trapped

The Surprising Upside

A 2016 Johns Hopkins study found that even among people who had a difficult experience, 84% rated it as among the top five most meaningful experiences of their lives. Difficult does not equal damaging — especially with good support and integration.

Reducing Risk

• Start with lower doses
• Prepare your set and setting thoroughly
• Have a trusted sitter
• Learn grounding techniques beforehand
• Save the Fireside Project number: 62-FIRESIDE

See our guide on Navigating Difficult Experiences for detailed techniques.

Duration depends on the substance, dose, your metabolism, and whether you’ve eaten.

Psilocybin (Mushrooms)

Phase	Duration
Onset	20–60 minutes
Peak	2–3 hours after onset
Comedown	4–6 hours total
Afterglow	1–3 days

LSD

Phase	Duration
Onset	30–90 minutes
Peak	3–5 hours after onset
Comedown	8–12 hours total
Afterglow	1–3 days

MDMA

Phase	Duration
Onset	30–60 minutes
Peak	1.5–3 hours
Comedown	4–6 hours total
Recovery	1–7 days (serotonin depletion can cause low mood)

DMT (Vaporized)

Phase	Duration
Onset	Seconds
Peak	2–10 minutes
Return to baseline	20–40 minutes

Important: Block out the full duration plus the day after. Even when acute effects end, you may feel tired, emotionally raw, or unusually open. Making decisions, driving, or working during this window is inadvisable.

In most of the world, psilocybin, LSD, MDMA, and DMT remain illegal for general use.

United States

Federal law: All classical psychedelics are Schedule I controlled substances under the Controlled Substances Act. This means they are illegal to manufacture, possess, or distribute, with severe penalties.

State and local exceptions:

• Oregon: Legalized adult use of psilocybin through licensed service centers (Measure 109, effective 2023). You must be 21+, and use must occur at a licensed facility with a trained facilitator.
• Colorado: Decriminalized personal use and cultivation of psilocybin, with a regulated access program being implemented.
• Local decriminalization: Several cities (Denver, Oakland, Santa Cruz, Ann Arbor, Seattle, and others) have deprioritized enforcement of psilocybin possession.

Clinical trials: Federally approved clinical trials are ongoing and legal for participants. Search ClinicalTrials.gov for “psilocybin” or “MDMA” in your area.

International

• Netherlands: Psilocybin truffles (not mushrooms) are legal and sold in smart shops.
• Jamaica, Bahamas: Unregulated; retreat centers operate legally.
• Brazil: Ayahuasca is legal for religious use.
• Peru, Costa Rica: Ayahuasca retreats operate in legal gray areas or with specific religious exemptions.
• Canada: Psilocybin is illegal but accessible through Health Canada’s Special Access Program in some cases, and some provinces have deprioritized enforcement.
• Australia: Since 2023, psilocybin can be prescribed by authorized psychiatrists for treatment-resistant depression.

The bottom line: You are responsible for knowing your local laws. This site provides educational information only and does not encourage illegal activity.

For people interested in psychedelics for mental health, clinical trials and legal retreats offer the safest and most legitimate paths.

Clinical Trials

Federally approved clinical trials provide legal access to psychedelics in controlled, supervised settings. Participation is free, and you’ll receive professional support throughout.

Where to find trials:

• ClinicalTrials.gov — search “psilocybin,” “MDMA,” or “psychedelic” plus your condition
• MAPS — MDMA-assisted therapy trials
• Johns Hopkins Center for Psychedelic and Consciousness Research
• Usona Institute — psilocybin for depression trials

What to expect:

• Rigorous screening (you may be excluded for certain conditions)
• Multiple preparation sessions
• One to three supervised dosing sessions
• Integration therapy afterward
• Follow-up assessments for months or years

Legal Retreats and Service Centers

Oregon Psilocybin Service Centers: Under Measure 109, adults 21+ can legally consume psilocybin at state-licensed service centers with trained facilitators. This is not clinical therapy — facilitators cannot diagnose or treat — but it is a legal, supervised container.

International Retreats:

• Jamaica: Several reputable psilocybin retreat centers operate legally.
• Netherlands: Psilocybin truffles are legal; various retreat centers exist.
• Peru / Costa Rica: Ayahuasca retreats are common, but quality and safety vary enormously. Research thoroughly.

Red flags for retreats:

• No medical screening
• No integration support
• Pressure to dose higher than you’re comfortable with
• Facilitators who dose with participants
• No emergency protocols
• Cult-like dynamics or guru worship

Cost

Clinical trials are typically free. Legal service centers and retreats range from hundreds to several thousand dollars.

The Honest Tradeoff

Legal routes are slower, more expensive, and involve more structure. They are also dramatically safer and more likely to produce lasting benefit than unguided use. For people with significant mental health conditions, we strongly encourage exploring legal avenues first.

If you have an established therapeutic relationship and are considering or have used psychedelics, the honest answer is: yes, probably.

Here’s why:

Your therapist can’t help with what they don’t know. Psychedelic experiences can surface trauma, shift your worldview, or destabilize you temporarily. Your therapist needs this context to support you effectively.

Confidentiality protects you. In the US, therapist-client confidentiality means your disclosures about personal psychedelic use are generally protected. Exceptions exist for imminent danger to self or others, child/elder abuse, and some court orders — but simply discussing psychedelic use does not trigger reporting.

Integration support matters. Even therapists without specific psychedelic training can help you process insights, stabilize after difficult experiences, and translate realizations into behavioral change.

If you’re worried about judgment:

• Consider framing it as harm reduction: “I’m exploring this and want professional support to do it safely.”
• If your therapist responds with punitive stigma rather than clinical curiosity, that may signal a poor therapeutic fit — not a reason to hide information, but a reason to seek a different provider.

If you don’t have a therapist: Consider establishing care before a psychedelic experience, especially if you have any mental health history. The MAPS Integration List and Psychedelic.Support can help you find psychedelic-informed providers.

See our guide on Talking to Your Doctor for more on how to have these conversations.